Dual Therapy with Insulin-Like Growth Factor-I Receptor/Insulin Receptor (IGF1R/IR) and Androgen Receptor (AR) Antagonists Inhibits Triple-Negative Breast Cancer Cell Migration In Vitro

Hamilton, Nalo; Márquez-Garbán, Diana C.; Rogers, Ben; Austin, David; Foos, Kay; Tong, Ashley L.; Adams, Diana; Vadgama, Jaydutt V.; Brecht, Mary‐Lynn; Pietras, Richard J.

doi:10.32392/biomed.69

Cited by 1 publication

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With an increasing number of BC MRS targeting IR, e.g., anti-idiotypic antibodies [ 64 ], combined therapy of IGF1R and IR antagonists may be able to optimize the therapeutic effect [ 65 ]. New findings indicated that combinations of IGF1R/IR with androgen receptor antagonist or anti-PD-L1, are effective in hindering migration and progression of TNBC cells [ 66 , 67 ]. However, IGF1R and IR therapies can cause worrying side effects.…”

Section: Mrs Targeting Glucose Metabolismmentioning

confidence: 99%

Potential Therapies Targeting the Metabolic Reprogramming of Diabetes-Associated Breast Cancer

Shum

Vadgama

et al. 2023

JPM

Self Cite

View full text Add to dashboard Cite

In recent years, diabetes-associated breast cancer has become a significant clinical challenge. Diabetes is not only a risk factor for breast cancer but also worsens its prognosis. Patients with diabetes usually show hyperglycemia and hyperinsulinemia, which are accompanied by different glucose, protein, and lipid metabolism disorders. Metabolic abnormalities observed in diabetes can induce the occurrence and development of breast cancer. The changes in substrate availability and hormone environment not only create a favorable metabolic environment for tumorigenesis but also induce metabolic reprogramming events required for breast cancer cell transformation. Metabolic reprogramming is the basis for the development, swift proliferation, and survival of cancer cells. Metabolism must also be reprogrammed to support the energy requirements of the biosynthetic processes in cancer cells. In addition, metabolic reprogramming is essential to enable cancer cells to overcome apoptosis signals and promote invasion and metastasis. This review aims to describe the major metabolic changes in diabetes and outline how cancer cells can use cellular metabolic changes to drive abnormal growth and proliferation. We will specifically examine the mechanism of metabolic reprogramming by which diabetes may promote the development of breast cancer, focusing on the role of glucose metabolism, amino acid metabolism, and lipid metabolism in this process and potential therapeutic targets. Although diabetes-associated breast cancer has always been a common health problem, research focused on finding treatments suitable for the specific needs of patients with concurrent conditions is still limited. Most studies are still currently in the pre-clinical stage and mainly focus on reprogramming the glucose metabolism. More research targeting the amino acid and lipid metabolism is needed.

show abstract

Section: Mrs Targeting Glucose Metabolismmentioning

confidence: 99%

Potential Therapies Targeting the Metabolic Reprogramming of Diabetes-Associated Breast Cancer

Shum

Vadgama

et al. 2023

JPM

Self Cite

View full text Add to dashboard Cite

show abstract

Dual Therapy with Insulin-Like Growth Factor-I Receptor/Insulin Receptor (IGF1R/IR) and Androgen Receptor (AR) Antagonists Inhibits Triple-Negative Breast Cancer Cell Migration In Vitro

Abstract: Background: Few targeted therapies are currently available for triplenegative breast cancers (TNBC) due to their lack of estrogen receptor-α and progesterone receptor expression and HER-2 amplification. In the clinic, TNBC is associated with a range of adverse biologic features

Cited by 1 publication

References 49 publications

Potential Therapies Targeting the Metabolic Reprogramming of Diabetes-Associated Breast Cancer

Potential Therapies Targeting the Metabolic Reprogramming of Diabetes-Associated Breast Cancer

Contact Info

Product

Resources

About